Lennox-Gastaut%252525252525252525252525252525252525252520syndrome

# Lennox-Gastaut Syndrome (LGS) ## Overview LGS is a severe form of childhood-onset epilepsy characterized by multiple seizure types (tonic, atonic, absence), cognitive impairment, and a characteristic slow spike-and-wave pattern on EEG. Management is typically polypharmacy-based, as monotherapy is rarely effective. ## Primary Indications Adjunctive therapy for seizures associated with LGS in patients ≥1 year of age. **Commonly utilized agents:** Rufinamide, Clobazam, Cannabidiol (CBD), Felbamate, Topiramate, Lamotrigine, and Valproate. ## Adult Dosing * **Rufinamide:** Start 400–800 mg/day divided BID; titrate by 400–800 mg every 2 days to a max of 3,200 mg/day (divided BID). * **Clobazam:** 5–10 mg/day; may titrate to 20 mg/day (divided). Max 40 mg/day. * **Cannabidiol (Epidiolex):** Start 5 mg/kg BID (10 mg/kg/day); increase to 10 mg/kg BID (20 mg/kg/day) after 1 week. ## Pediatric Dosing (≥1 year) * **Rufinamide:** Start ~10 mg/kg/day divided BID; titrate in 10 mg/kg increments every 2 days to a max of 45 mg/kg/day (not to exceed 3,200 mg/day). * **Clobazam:** 0.25–1 mg/kg/day. Target ~0.5–1 mg/kg/day. Max 40 mg/day for patients >30 kg; max 20 mg/day for patients ≤30 kg. * **Cannabidiol:** Same as adult dosing (20 mg/kg/day total). ## Dose Adjustments * **Renal/Hepatic:** Frequent adjustments required (e.g., Felbamate/Valproate require hepatic monitoring; Rufinamide/Topiramate require renal assessment). * **Drug Interactions:** Dose reductions often necessary when combined with valproate (e.g., Rufinamide, Clobazam) due to inhibition of metabolic clearances. ## Contraindications * **Rufinamide:** Familial Short QT syndrome. * **Felbamate:** Known hepatic impairment or history of aplastic anemia. * **General:** Hypersensitivity to active ingredients or excipients. ## Adverse Effects * **Common:** Somnolence, dizziness, fatigue, ataxia, and gastrointestinal distress. * **Severe:** Suicidal ideation (all anticonvulsants), hepatotoxicity (Valproate, Felbamate), aplastic anemia (Felbamate), and DRESS syndrome (Lamotrigine, Rufinamide). ## Key Drug Interactions * **Valproate:** Potent enzyme inhibitor; increases concentrations of lamotrigine, rufinamide, and clobazam (via CYP2C19 inhibition). * **CYP Inducers (e.g., Phenytoin, Carbamazepine):** Decrease drug concentrations (e.g., clobazam, cannabidiol). * **CNS Depressants:** Additive sedation with clobazam and other anti-seizure medications. ## Monitoring * **Baseline/Routine:** Liver function tests (LFTs), CBC (for hematologic toxicity), and weight-based monitoring. * **Cardiac:** EKG for patients on rufinamide. * **Behavioral:** Screen for new or worsening depression or suicidality. ## Clinical Pearls * **Polysymptomatic approach:** No single agent is curative; therapy must balance efficacy against the significant side-effect burden of polypharmacy. * **Tapering:** Never abruptly discontinue anti-seizure medications; risk of status epilepticus. * **Cannabidiol Caution:** Requires monitoring for LFT elevations, especially when co-administered with valproate. * **Protocol Variance:** Institutional protocols often dictate specific titration schedules and first-line preferences. Always consult local standard-of-care guidelines. *** **DISCLAIMER:** This information is for educational purposes only. Prescribing information, dosing, and clinical guidelines change frequently. Verify all dosages, contraindications, and drug interactions against the most current manufacturer labeling, institutional protocols, and peer-reviewed clinical literature before administration.